ReviewExpert opinion on investigational drugs2010
Pirfenidone: an anti-fibrotic therapy for progressive kidney disease.
Review in Expert opinion on investigational drugs, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pirfenidone Effect on the Recovery of Renal Function in Patients With Septic Acute Kidney Injury
Trial of Pirfenidone to Prevent Progression in Chronic Kidney Disease (TOP-CKD)
Who cites it
43 citing papers in PubMed, 103 citations in OpenAlex.
- Effect of GLPG1205, a GPR84 Modulator, on CYP2C9, CYP2C19, and CYP1A2 Enzymes: In Vitro and Phase 1 Studies.Clinical pharmacology in drug development · 2021Trial
- Therapeutic Potential of Pirfenidone in Adenine-Induced Chronic Kidney Disease: An Integrated Experimental and In Silico Study.Applied biochemistry and biotechnology · 2026Article
- Efficacy of finerenone in reducing proteinuria in diabetic kidney disease on dapagliflozin and telmisartan: A disease-modifying approach.World journal of nephrology · 2026Review
- Integrative Perspectives on Pirfenidone: Mechanistic Insights, Pharmacodynamics, and Emerging Therapeutic Strategies for Fibrotic Disorders.AAPS PharmSciTech · 2026Review
- Lead-Induced Nephrotoxicity and Its Therapeutic Interventions: An Updated Review.Biological trace element research · 2026Review
- Beyond attenuation: a translational review of curative-intent pharmacological targets in idiopathic pulmonary fibrosis.Frontiers in medicine · 2026Review
- MICA-129Met/Val as a therapeutic compass in idiopathic pulmonary fibrosis: prognosis and antifibrotic benefit.Frontiers in immunology · 2026Article
- Transcriptome-Guided Drug Repurposing Identifies Homoharringtonine (HHT) as a Candidate for Radiation-Induced Pulmonary Fibrosis.Pharmaceutics · 2025Article
- Postoperative Adhesions: Current Research on Mechanisms, Therapeutics and Preventative Measures.Biomedical materials & devices (New York, N.Y.) · 2025Article
- Exploring the potential of herbal drugs for treating liver fibrosis: a computational screening approach.Asian biomedicine : research, reviews and news · 2025Article
- Review
- Pirfenidone use in fibrotic diseases: What do we know so far?Immunity, inflammation and disease · 2024Review
- Fibrosis in Chronic Kidney Disease: Pathophysiology and Therapeutic Targets.Journal of clinical medicine · 2024Review
- Evaluation of prevention and treatment effects of fibroblast growth factor-21 in BLM-induced pulmonary fibrosis.Naunyn-Schmiedeberg's archives of pharmacology · 2023Article
- Trials and Treatments: An Update on Pharmacotherapy for Idiopathic Pulmonary Fibrosis.Life (Basel, Switzerland) · 2023Review
- Development of antifibrotic therapy for stricturing Crohn's disease: lessons from randomized trials in other fibrotic diseases.Physiological reviews · 2022Review
- Phenotypic screening of 1,953 FDA-approved drugs reveals 26 hits with potential for repurposing for Peyronie's disease.PloS one · 2022Article
- New Drugs for Hepatic Fibrosis.Frontiers in pharmacology · 2022Review
- Recent Advances of Pyridinone in Medicinal Chemistry.Frontiers in chemistry · 2022Review
- Prevention of Post-Operative Adhesions: A Comprehensive Review of Present and Emerging Strategies.Biomolecules · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
importance of the fieldMany chronic diseases of various etiologies lead to fibrosis and organ dysfunction. Despite many advances in medicine in recent years, options to slow the progression of fibrotic diseases have remained limited. The recent availability of pirfenidone, an antifibrotic and anti-inflammatory investigational agent, thus offers a new hope for treating progressive fibrotic diseases. AREAS COVERED IN THIS REVIEW: This review provides concise review of the available data regarding the mechanism and pharmacokinetics of pirfenidone and preclinical and clinical data regarding efficacy and safety in fibrotic diseases of the kidney. It also reviews results of clinical trials involving pirfenidone in other fibrotic diseases. WHAT THE READER WILL GAIN: The review will provide in-depth review of pirfenidone with a renal focus. TAKE HOME MESSAGE: Because many of the available clinical trials have been small and/or uncontrolled, conclusive evidence regarding efficacy and safety of pirfenidone is lacking, particularly in patients with renal or hepatic dysfunction. Larger studies are needed to better understand long-term efficacy and safety of this medication in various patient populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.